Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583259 | 0.86 | KMT2A (0.42) | EGLN1KMT2AKMOFAAHASPH | |
| SCHEMBL1583236 | 0.85 | EGLN1 (0.33) | EGLN1KMT2AKMOASPHMAPT | |
| SCHEMBL3691065 | 0.85 | CFTR (0.40) | CFTRMAPTPKMKDM4ESMN1; SMN2 | |
| SCHEMBL1583276 | 0.84 | EPRS1 (0.35) | EGLN1KMT2AKMOCFTRASPH | |
| SCHEMBL13228924 | 0.82 | EGLN1 (0.31) | EGLN1KMT2AKMO | |
| SCHEMBL3684234 | 0.81 | RBP4 (0.35) | EGLN1MAPT | |
| SCHEMBL1583417 | 0.81 | RXFP1 (0.36) | EGLN1KMT2AFAAHMAPTPKM | |
| SCHEMBL1583294 | 0.81 | AKR1C3 (0.34) | EGLN1KMT2AMAPTPKM | |
| SCHEMBL3686175 | 0.81 | RORC (0.34) | EGLN1KMT2AKMOPKMMEN1 | |
| SCHEMBL3689623 | 0.81 | LDHA (0.43) | KMT2AKMOMAPTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | EGLN1 369/4885KMT2A 3145/4885KMO 2804/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | EGLN1 369/4885KMT2A 3145/4885KMO 2804/4885 |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | EGLN1 332/4885KMT2A 4584/4885KMO 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.